RAPP
Rapport Therapeutics, Inc.
25.10$
+0.3%
vs. previous close
Closing price · As of: Nov 2, 2026
Filings
Filings
Listed US companies must report material events to the Securities and Exchange Commission. This page lists the filings of Rapport Therapeutics, Inc. (RAPP) with date, type and a link to the original document.
| Date | Type | Filing | Original |
|---|---|---|---|
| 10/30/2026 | Current report (8-K) | Rapport Therapeutics, Inc. (RAPP): Entry into a Material Definitive Agreement; Results of Operations and Financial Condition; Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Unregistered Sales of Equity Securities; Financial Statements and Exhibits | View report ↗ |
| 10/30/2026 | Capital measure | Form 424B5 filed with the SEC | View document ↗ |
| 10/30/2026 | Capital measure | Form 424B5 filed with the SEC | View document ↗ |
| 10/27/2026 | Capital measure | Form 424B5 filed with the SEC | View document ↗ |
| 10/27/2026 | Capital measure | Form 424B5 filed with the SEC | View document ↗ |
| 10/20/2026 | Current report (8-K) | Rapport Therapeutics, Inc. (RAPP): Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View report ↗ |
| 10/06/2026 | Insider sale notice | Form 144 filed with the SEC | View document ↗ |
| 09/30/2026 | Insider sale notice | Form 144 filed with the SEC | View document ↗ |
| 08/25/2026 | Insider sale notice | Form 144 filed with the SEC | View document ↗ |
| 08/24/2026 | Insider sale notice | Form 144 filed with the SEC | View document ↗ |
| 08/19/2026 | Insider sale notice | Form 144 filed with the SEC | View document ↗ |
| 08/05/2026 | Current report (8-K) | Rapport Therapeutics, Inc. (RAPP): Results of Operations and Financial Condition; Financial Statements and Exhibits | View report ↗ |
Showing the 100 most recent filings of the selected type.
Data as of: November 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Filings: SEC EDGAR
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.